STOCK TITAN

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Allergan Aesthetics, an AbbVie company, is inviting consumers to participate in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē. The open casting call aims to feature authentic patient stories and increase diversity within the aesthetics industry. Consumers can apply until June 4, 2024, by submitting their application on www.alle.com/castingcall.
Allergan Aesthetics, una società di AbbVie, invita i consumatori a partecipare alle prossime campagne per i loro marchi più importanti, inclusi BOTOX® Cosmetic, la collezione di riempitivi JUVÉDERM® e Allē. La chiamata aperta per il casting mira a presentare storie autentiche di pazienti e ad aumentare la diversità nell'industria estetica. I consumatori possono candidarsi fino al 4 giugno 2024, inviando la loro domanda su www.alle.com/castingcall.
Allergan Aesthetics, una compañía de AbbVie, está invitando a los consumidores a participar en las próximas campañas para sus marcas más importantes, incluyendo BOTOX® Cosmetic, la Colección de Rellenos JUVÉDERM® y Allē. La convocatoria abierta de casting tiene como objetivo presentar historias auténticas de pacientes e incrementar la diversidad dentro de la industria estética. Los consumidores pueden aplicar hasta el 4 de junio de 2024, enviando su solicitud en www.alle.com/castingcall.
애브비(AbbVie)의 계열사인 알러간 에스테틱스가 BOTOX® 코스메틱, 주비덤® 필러 컬렉션, 알리 등 주요 브랜드를 위한 다가오는 캠페인에 소비자들을 초대합니다. 오픈 캐스팅 콜은 진정한 환자 이야기를 특징으로 하고 미용 업계 내 다양성을 증가시키기를 목표로 합니다. 소비자들은 2024년 6월 4일까지 www.alle.com/castingcall에서 신청서를 제출하여 참여할 수 있습니다.
Allergan Aesthetics, une entreprise d'AbbVie, invite les consommateurs à participer aux campagnes à venir pour leurs plus grandes marques, y compris BOTOX® Cosmetic, la Collection de Fillers JUVÉDERM® et Allē. L'appel de casting ouvert vise à mettre en avant des histoires authentiques de patients et à accroître la diversité dans l'industrie esthétique. Les consommateurs peuvent postuler jusqu'au 4 juin 2024 en soumettant leur candidature sur www.alle.com/castingcall.
Allergan Aesthetics, ein Unternehmen von AbbVie, lädt Verbraucher ein, an zukünftigen Kampagnen für ihre größten Marken teilzunehmen, einschließlich BOTOX® Cosmetic, der JUVÉDERM® Filler Kollektion und Allē. Der offene Casting-Aufruf zielt darauf ab, authentische Patientengeschichten zu präsentieren und die Vielfalt in der ästhetischen Industrie zu erhöhen. Verbraucher können sich bis zum 4. Juni 2024 bewerben, indem sie ihre Bewerbung auf www.alle.com/castingcall einreichen.
Positive
  • None.
Negative
  • None.
  • Consumers Can Apply for a Chance to Be Featured in Upcoming Campaigns for BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics Loyalty Rewards Program

IRVINE, Calif., April 23, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BOTOX® Cosmetic elicited approximately 20,000 submissions resulting in a powerful campaign focused on a diverse set of patients sharing heartfelt, authentic stories for why they pursued treatment.

"Following the success of our BOTOX® Cosmetic "See Yourself" campaign we are continuing our commitment to showcasing natural-looking results that real patients and their providers are able to achieve with our brands," said Jasson Gilmore, Senior Vice President, U.S. Aesthetics. "There is nothing more powerful than seeing someone you can relate to sharing their aesthetic journey. With this casting call, we are elevating more authentic patient voices while driving increased diversity across the entire the industry, with the goal of making this the standard for aesthetics."

Allergan Aesthetics is partnering with Cosmetic Executive Women (CEW), Black Beauty Roster, Latinas in Beauty, and The Black Beauty Club to promote the open casting to their members, giving real patients a platform to share their personal experiences.

"We are seeing a trend towards consumers demanding authenticity from beauty, cosmetic, and aesthetic companies. Allergan Aesthetics is the only company we are aware of that is driving that effort in the aesthetics category, where we feel this level of transparency and representation is essential," said The Black Beauty Club co-founders Tomi Talabi and Asmeret Berhe-Lumax. "We are thrilled to see a company like Allergan Aesthetics listen to the voices of our members, and the members of other organizations like ours, to drive real change in how aesthetic products and treatments are marketed. We know this authentic approach to engaging with consumers and reflecting their voices is essential."

Content from these campaigns will include personal testimonials, before and after treatment videos and imagery, behind-the-scenes footage, self-filmed treatment diaries, and a before and after series for YouTube and other social media platforms.

Allergan Aesthetics open casting call will run through June 4, 2024, closing at 11:59 p.m. EDT. Anyone interested is encouraged to apply by submitting their application at www.alle.com/castingcall. The final cast for each brand will be announced later this year.

BOTOX® Cosmetic Important Information

APPROVED USES

BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.

BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION

BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

  • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection.
  • Swallowing problems may last for several months.
  • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines.

BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic.

Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.

Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes.

For more information refer to the Medication Guide or talk with your doctor.

To report a side effect, please call Allergan at 1-800-678-1605.

Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide.

JUVÉDERM® Injectable Gel Fillers Important Information

APPROVED USES

JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss, for augmentation of the chin region to improve the chin profile, and for augmentation of the temple region to improve moderate to severe temple hollowing in adults over 21.

JUVÉDERM® VOLUX® XC injectable gel is for deep injection to improve moderate to severe loss of jawline definition in adults over the age of 21. 

JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC injectable gels are for injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. JUVÉDERM® VOLLURE® XC injectable gel is for adults over 21.

JUVÉDERM® Ultra XC injectable gel is also for injection into the lips and perioral area for lip augmentation in adults over 21.

JUVÉDERM® VOLBELLA® XC injectable gel is for injection into the lips for lip augmentation and correction of perioral lines, and for injection into the undereye hollows to improve the appearance of undereye hollows in adults over the age of 21.

IMPORTANT SAFETY INFORMATION

Are there any reasons why I should not receive any JUVÉDERM® formulation?
Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), if you are allergic to lidocaine or the Gram-positive bacterial proteins used in these products, or if you have had previous allergic reactions to hyaluronic acid fillers.

What warnings should my doctor advise me about?

  • One of the risks with using dermal fillers is the unintentional injection into a blood vessel. The chances of this happening are very small, but if it does happen, the complications can be serious and may be permanent. These complications, which have been reported for facial injections, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. Most of these events are irreversible.
  • If you have changes in your vision, signs of a stroke (including sudden difficulty speaking, numbness or weakness in your face, arms or legs, difficulty walking, face drooping, severe headache, dizziness, or confusion), white appearance of the skin, or unusual pain during or shortly after treatment, you should notify your health care practitioner immediately.
  • The use of dermal fillers where skin sores, pimples, rashes, hives, cysts, or infections are present should be postponed, as this may delay healing or make skin problems worse.
  • The effectiveness of removal of any dermal filler has not been studied.

What precautions should my doctor advise me about?

  • JUVÉDERM® VOLBELLA® XC should only be injected into undereye hollows by doctors who have completed the necessary training for this treatment area. To find a doctor, visit Juvederm.com/find-a-specialist. Doctors who complete the training will be listed with a symbol
  • The safety of these products for use during pregnancy or while breastfeeding has not been studied
  • The safety of JUVÉDERM® VOLUMA® XC has not been studied in patients under 35 years or over 65 years for cheek augmentation, under 22 years or over 80 years for chin augmentation, and under 32 years or over 82 years for temple area augmentation. The safety of JUVÉDERM® VOLUX® XC, JUVÉDERM® VOLLURE® XC and JUVÉDERM® VOLBELLA® XC has not been studied in patients under 22 years, and the safety of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC has not been studied in patients under 18 years
  • The safety and effectiveness of treatment with JUVÉDERM® products in anatomical regions outside of their approved uses have not been established in clinical studies
  • If you have a history of excessive scarring (thick, hard scars) or pigmentation disorders, treatment in these patients has not been studied and may result in additional scars or changes in pigmentation
  • If you are planning other procedures including laser treatments or a chemical peel, there is a possible risk of inflammation at the treatment site if these procedures are performed closely before or after JUVÉDERM® injectable gel treatment
  • Tell your doctor if you are on therapy used to reduce your body's natural defense system (such as steroids, chemotherapy, and medicines to treat autoimmune diseases, HIV, and AIDs), as these may increase your risk of infection; and medications that can prolong bleeding (such as aspirin, ibuprofen, or other blood thinners), as these may result in increased bruising or bleeding at the injection site.
  • Avoid applying makeup for 12 hours after treatment and minimize strenuous exercise, exposure to extensive sun or heat, and alcoholic beverages within the first 24 hours following treatment, as these may cause temporary redness, swelling, and/or itching at the injection site
  • JUVÉDERM® VOLUMA® XC was not studied in patients with significant loose skin of the chin, neck, or jaw
  • The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
  • Patients who experience skin injury near the site of JUVÉDERM® VOLUMA® XC injection may be at a higher risk for adverse events
  • Tell your doctor if you have already been injected with dermal fillers in the same area as the one(s) you are about to be treated for. This information helps your doctor decide when and whether you should get treatment

What are possible side effects of treatment?
The most commonly reported side effects with JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported.

These side effects are consistent with other facial injection procedures and most will resolve within 30 days. Your doctor may choose to treat side effects persisting longer with antibiotics, steroids, or hyaluronidase (an enzyme that breaks down hyaluronic acid).

As with all skin injection procedures, there is a risk of infection.

To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372. Please also visit Juvederm.com or talk to your doctor for more information.

Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

Allergan Aesthetics (PRNewsfoto/AbbVie)

BOTOX® Cosmetic (onabotulinumtoxinA) (PRNewsfoto/AbbVie)

JUVÉDERM® Collection of Fillers logo (PRNewsfoto/AbbVie)

Allē logo

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-invites-consumers-to-be-the-face-of-botox-cosmetic-onabotulinumtoxina-and-their-other-biggest-brands-302123978.html

SOURCE AbbVie

FAQ

How can consumers participate in upcoming campaigns for Allergan Aesthetics brands?

Consumers can apply to be featured in upcoming campaigns for BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē by submitting their application on www.alle.com/castingcall.

What is the deadline for applying to be part of the Allergan Aesthetics open casting call?

The deadline for applying to be part of the Allergan Aesthetics open casting call is June 4, 2024, at 11:59 p.m. EDT.

What organizations is Allergan Aesthetics partnering with for the open casting call promotion?

Allergan Aesthetics is partnering with Cosmetic Executive Women (CEW), Black Beauty Roster, Latinas in Beauty, and The Black Beauty Club for the open casting call promotion.

What type of content will be included in the campaigns featuring authentic patient stories?

Content from the campaigns will include personal testimonials, before and after treatment videos and imagery, behind-the-scenes footage, self-filmed treatment diaries, and a before and after series for YouTube and other social media platforms.

What are the approved uses of BOTOX® Cosmetic?

BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.

What are some important safety information regarding BOTOX® Cosmetic?

BOTOX® Cosmetic may cause serious side effects that can be life-threatening, including problems swallowing, speaking, or breathing, spread of toxin effects, and allergic reactions. Consumers should consult with a healthcare professional before using BOTOX® Cosmetic.

What should consumers do if they experience side effects after using BOTOX® Cosmetic?

Consumers should seek medical help immediately if they experience side effects such as problems swallowing, speaking, breathing, vision problems, or allergic reactions after using BOTOX® Cosmetic.

What should consumers avoid before using BOTOX® Cosmetic?

Consumers should not receive BOTOX® Cosmetic if they are allergic to any of its ingredients, had an allergic reaction to other botulinum toxin products, or have a skin infection at the planned injection site.

ABBVIE INC.

NYSE:ABBV

ABBV Rankings

ABBV Latest News

ABBV Stock Data

284.74B
1.76B
0.11%
71.92%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NORTH CHICAGO

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.